ASRS 2023: Diana Do, MD, shares update on PHOTON study for diabetic macular edema
July 30th 2023Diana Do, MD, professor of ophthalmology and vice chair of clinical affairs at the Byers Eye Institute at Stanford University, spoke with our team about the 2-year data on the PHOTON study, which involved 8 milligrams of aflibercept for diabetic macular edema at the 2023 ASRS meeting in Seattle, Washington.
Read More
ASRS 2023: GATHER 1 and GATHER 2 clinical trial for geographic atrophy results
July 29th 2023At the 2023 ASRS meeting in Seattle, Washington, Carl Danzig, MD, caught up with our team to share the exciting results of the GATHER 1 and GATHER 2 clinical trials for avacincaptad pegol for the treatment of geographic atrophy.
Read More
ASRS 2023: Deep learning models and the importance of training from imaging datasets
July 29th 2023Aaron Lee, MD, shared how research and new techniques are expanding the options for deep learning in ophthalmology. He spoke with our team at the 2023 ASRS meeting in Seattle, Washington to share more about this research.
Read More
ASRS 2023: Annexon to share results of ARCHER Phase 2 trial for the treatment of geographic atrophy
July 26th 2023The presenter, Jeffrey S. Heier, MD, Director of the Retina Service and Retina Research, Ophthalmic Consultants of Boston, and an investigator in ARCHER will deliver the data on July 30, 2023.
Read More
Opthea’s OPT-302 to be featured in oral presentation during ASRS 2023
July 17th 2023The oral presentation, entitled “Population Pharmacokinetics and Safety of OPT-302, an anti-VEGF-C/-D ‘trap’ in Patients with Retinal Vascular Diseases” will take place on July 31, 2023 in Seattle, Washington.
Read More
Apellis Pharmaceutical to share data during oral presentations at ASRS 2023 in Seattle
July 14th 2023Apellis has announced that seven abstracts will be presented at the American Society of Retina Specialists Annual Scientific Meeting including safety and efficacy data for the company’s pegcetacoplan injection for geographic atrophy (GA).
Read More
Alumis begins patient dosing in OPTYK-1 Phase 2 clinical trial for the treatment of uveitis
July 9th 2023This allosteric tyrosine kinase (TYK2) inhibitor may help to treat the disregulation of TYK2 mediated pathways may also play an important role in conditions, including noninfectious uveitis.
Read More
EyeCare Partners launches Advanced Comprehensive Ophthalmology Fellowship and opens applications
July 5th 2023The fellowship is a one-year program that will provide comprehensive training to residency graduates in the latest advancements in ophthalmology, including diagnostic and therapeutic techniques, surgical procedures, and clinical research.
Read More
20/20 Onsite earned site readiness certification, providing mobile option for clinical trials
June 26th 2023The certification will allow 20/20 Onsite to make clinical trials more accessible to patients nationwide and expand site options for sponsors while maintaining performance and data collection standards, including BCVA and DR testing.
Read More
EyeBio dosed first participants for Phase 1b/2 AMARONE clinical trial for DME and nAMD
June 17th 2023EyeBio has begun the dosing of the first participants in its Phase 1b/2 AMARONE clinical trial for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).
Read More
Bausch + Lomb announces U.S. launch of PreserVision AREDS 2 Formula Soft Gels Plus CoQ10
June 13th 2023This two-in-one option, PreserVision AREDS 2 Formula eye vitamins plus CoQ10 combines the exact nutrient formula recommended by the National Eye Institute (NEI) to help reduce the risk of moderate to advanced Age-related Macular Degeneration (AMD) progression.
Read More